Preferred Name

Silmitasertib

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C98054

CAS_Registry

1009820-21-6

Chemical_Formula

C19H12ClN3O2

code

C98054

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

Contributing_Source

GDC

FDA

DEFINITION

An orally bioavailable small-molecule inhibitor of the enzyme casein kinase II (CK2), with potential antineoplastic, anti-viral and immunomodulatory activities. Upon oral administration, silmitasertib selectively binds to and inhibits the activity of CK2. This may inhibit proliferation of CK2-expressing tumor cells, and may also inhibit the replication of severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). In addition, this may restore normal host cell cytokine regulation, prevent cytokine storm and suppress the hyperactivation of the innate immune system. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. CK2 regulates a diverse array of pro-survival cellular processes including epidermal growth factor receptor (EGFR) signaling, PI3K/AKT/mTOR signaling, hedgehog (Hh) signaling, Hsp90 machinery, hypoxia, and interleukin (IL)-6 expression. CK2 also regulates the activity of XRCC1 and MDC1, two mediator/adaptor proteins that are essential for DNA repair. CK2 is upregulated by SARS-COV-2 and is associated with SARS-COV-2 viral replication and the development of cytokine storm.

FDA_UNII_Code

C6RWP0N0L2

FULL_SYN

CX 4945

5-((3-chlorophenyl)amino)-benzo(c)-2,6-naphthyridine-8-carboxylic Acid

CX-4945

SILMITASERTIB

CX4945

Silmitasertib

Has_Salt_Form

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C85460

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107559

label

Silmitasertib

Preferred_Name

Silmitasertib

prefixIRI

Thesaurus:C98054

prefLabel

Silmitasertib

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C2974252

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61074

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://purl.bioontology.org/ontology/MESH/C555142 Medical Subject Headings / 医学主题词表 LOOM